Bactrian ("double hump") acetaminophen pharmacokinetics: a case series and review of the literature.
After acute ingestion, acetaminophen (APAP) is generally absorbed within 4 h and the APAP concentration ([APAP]) slowly decreases with a predictable half-life. Alterations in these pharmacokinetic principles have been rarely reported. We report here three cases of an unusual double hump, or Bactrian, pattern of [APAP]. We review the literature to describe the case characteristics of these rare cases. A 38-year-old woman ingested 2 g hydrocodone/65 g acetaminophen. Her [APAP] peaked at 289 mcg/mL (8 h), decreased to 167 mcg/mL (31 h), then increased to 240 mcg/mL (39 h). She developed liver injury (peak AST 1603 IU/L; INR1.6). A 25-year-old man ingested 2 g diphenhydramine/26 g APAP. His [APAP] peaked at 211 mcg/mL (15 h), decreased to 185 mcg/mL (20 h), and increased again to 313 mcg/mL (37 h). He developed liver injury (peak AST 1153; INR 2.1). A 16-year-old boy ingested 5 g diphenhydramine and 100 g APAP. His [APAP] peaked at 470 mcg/mL (25 h), decreased to 313 mcg/mL (36 h), then increased to 354 mcg/mL (42 h). He developed liver injury (peak AST 8,686 IU/L; peak INR 5.9). We report three cases of Bactrian ("double hump") pharmacokinetics after massive APAP overdoses. Cases with double hump pharmacokinetics may be associated with large ingestions (26-100 g APAP) and are often coingested with antimuscarinics or opioids. Several factors may contribute to these altered kinetics including the insolubility of acetaminophen, APAP-induced delays in gastric emptying, opioid or antimuscarinic effects, or enterohepatic circulation. Patients with double hump APAP concentrations may be at risk for liver injury, with AST elevations and peaks occurring later than what is typical for acute APAP overdoses.
Hendrickson
Robert G
RG
Oregon Poison Center, Portland, OR 97210, USA. hendriro@ohsu.edu
McKeown
Nathanael J
NJ
West
Patrick L
PL
Burke
Christopher R
CR
D000082:Acetaminophen / Q000493:pharmacokinetics* / Q000506:poisoning; D000293:Adolescent; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000493:pharmacokinetics*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male
D018712:Analgesics, Non-Narcotic; D000082:Acetaminophen
Ann Emerg Med. 1996 Nov;28(5):549-51
8909277
Ann Emerg Med. 2007 Sep;50(3):280-1
17418449
JAMA. 1969 Jan 13;207(2):361-2
5818163
Clin Pharmacokinet. 2002;41(10):751-90
12162761
Clin Pharmacol Ther. 1982 Feb;31(2):151-6
7056022
Am J Emerg Med. 2004 Nov;22(7):548-54
15666259
Acad Emerg Med. 2005 Feb;12(2):169-72
15692141
J Toxicol Clin Toxicol. 2002;40(1):3-20
11990202
Cancer Invest. 1996;14(3):202-10
8630680
Br J Clin Pharmacol. 1985 Jun;19(6):767-73
4027120
J Emerg Med. 2006 Jan;30(1):1-5
16434328
Vet Hum Toxicol. 2001 Aug;43(4):218-9
11474737
J Toxicol Clin Toxicol. 1994;32(4):431-4
7914547
Ann Emerg Med. 2009 Sep;54(3):421-3
18986731
Am J Emerg Med. 1999 May;17(3):315-7
10337903
J Toxicol Sci. 2008 Dec;33(5):549-53
19043276
Ann Emerg Med. 1995 Jul;26(1):49-53
7793720
Clin Toxicol (Phila). 2008 Apr;46(4):317-9
18363128
J Pharm Sci. 1983 Aug;72(8):955-8
6688635
Ann Pharmacother. 2008 Sep;42(9):1333-9
18628444
J Pharmacokinet Biopharm. 1983 Jun;11(3):245-72
6644552
Arch Intern Med. 1984 Feb;144(2):402-3
6696579
N Engl J Med. 1988 Dec 15;319(24):1557-62
3059186
Xenobiotica. 1983 Oct;13(10):591-6
6673372